Sanofi lifts sales potential of blockbuster drug to USD 14.5bn

When Paul Hudson, a British national, took over at the helm of French pharmaceutical company Sanofi back in June 2019, it was said that multi-blockbuster Dupixent could reach top sales of USD 11bn.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
IGM Biosciences and Sanofi enter deal with USD 6bn potential
For subscribers